Europa da marcha atrás y recommenda ahora aprobar lecanemab, el primer pharmaco contra el alzheimer en decasas

La Agencia Europea de Medicamentos (EMA) recommends approval. lecanemabit will be the first anti-Alzheimer drug in Europe for decades. Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA, por sus siglas en inglés) Allow me For Lequembi (nombrecomercial) la ralentización del deterioro cognitivo consigido for “Resgo de efectos secundarios graves asociados con el medicamento” without any contradiction.

The EMA decided this time to give the original decision to Biogen and Eisai, the pharmaceutical companies behind the duplicate drugs. In July, the EMA committee concluded that images related to amyloid or ARIA can cause inflammation and microhemorrhages in the brain You need the administration to get the motivation you need to get approved.

Tal y como contamos en EL ESPAÑOLBiogen and Eisai, the pharmaceutical companies developing lecanemab, submitted to the agency a study of 1,795 people with early stages of Alzheimer's disease who were randomly assigned either the drug or a placebo. Tras año y medio de studio, aquellos que accepted Legembi sufrieron un 1.21 cognitive rate combined with CDR-SBwhich is used to evaluate this concept in the patient and has a maximum of 18 points.

After 1.66 minutes of placebo, the EMA considered the difference to be insufficiently significant.

The truth is that for decades Alzheimer's research has been trying to slow or stop the progression of the disease. In this sense, lecanemab is the first drug to be demonstrated clinical benefits.

Este monoclonal antibody se dirige to eliminate the brain's beta-amyloid protein, a marker for Alzheimer's. It is the first drug that can stop the deterioration and at the same time change the course of the disease, because to reduce beta amyloid deposits in the brain, 27% were cognitively impaired en personas con la enfermedad o con deterioro cognitivo leve.

Notice and update

We are working on expanding this information. In short, the editorial staff of EL ESPAÑOL will offer to update all information related to this news.

You can download the program from our newspaper to get the latest news on your mobile phone iOS devices y Androidso Subscribe to access exclusive contentrecibir nuestras Newsletters y disfrutar de la Zona Ñ, for solo subscribers.